Effectiveness of endopeptidase inhibition (Candoxatril) in congestive heart failure
- 15 August 1992
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 70 (4), 494-498
- https://doi.org/10.1016/0002-9149(92)91196-b
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Inhibition of Neutral Endopeptidase (EC 3.4.24.11) Leads to An Atrial Natriuretic Factor-Mediated Natriuretic, Diuretic and Antihypertensive Response in RodentsClinical Science, 1991
- EFFECTS OF UK 69 578: A NOVEL ATRIOPEPTIDASE INHIBITORThe Lancet, 1989
- Hemodynamic, renal and endocrine effects of atrial natriuretic peptide infusion in severe heart failureJournal of the American College of Cardiology, 1988
- Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects.Circulation, 1988
- Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidneyPeptides, 1988
- Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function.Circulation, 1987
- The hydrolysis of α-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11Biochemical Journal, 1987
- HAEMODYNAMIC EFFECTS OF ATRIAL PEPTIDE INFUSION IN HEART FAILUREThe Lancet, 1986
- Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion.Journal of Clinical Investigation, 1986
- Human Atrial Natriuretic PeptideJournal of Cardiovascular Pharmacology, 1986